![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, May 28, 2020 9:57:56 PM
NuCana Presenting at 2020 Jefferies Virtual Healthcare Conference
Presentation Date: Wednesday, June 3, 2020
Presentation Time: 10:00 AM ET
About NuCana plc
NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
I am not an accountant. I’m just a retiree with a computer and an Internet connection. No part of this site’s content should be construed as advice, and you should not take anything that is said here as investment or financial advice.
Recent NCNA News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/18/2024 08:02:56 PM
- NuCana to Present at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:36:30 PM
- NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit • GlobeNewswire Inc. • 05/21/2024 12:00:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/16/2024 08:11:50 PM
- NuCana Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/16/2024 08:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/13/2024 08:13:55 PM
- NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 05/01/2024 08:01:00 PM
- NuCana Announces Completion of ADS Ratio Change • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study • GlobeNewswire Inc. • 04/09/2024 08:30:00 PM
- NuCana Announces Plan to Implement ADS Ratio Change • GlobeNewswire Inc. • 03/27/2024 08:30:00 PM
- NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/20/2024 08:01:00 PM
- NuCana to Present at TD Cowen’s 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
- NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/16/2023 09:08:52 PM
- NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/16/2023 09:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 09:22:50 PM
- NuCana Announces Listing Transfer to Nasdaq Capital Market • GlobeNewswire Inc. • 11/10/2023 09:01:00 PM
- NuCana to Present at the Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 09:01:00 PM
- NuCana to Participate in the Truist Securities 2023 BioPharma Symposium • GlobeNewswire Inc. • 11/01/2023 08:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/16/2023 11:10:58 AM
- NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 • GlobeNewswire Inc. • 10/16/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/13/2023 08:09:55 PM
- NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 • GlobeNewswire Inc. • 10/13/2023 04:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/18/2023 12:10:56 PM
- NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 • GlobeNewswire Inc. • 09/18/2023 12:00:00 PM
FEATURED North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • Jul 18, 2024 9:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM